MDT-AP-1168
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 27
- os_event
- false
- age_years
- 8.44
- sex
- M
- new_clusters
- C4
- umap1_2d
- 4.161576926
- umap2_2d
- 4.5279736
- umap1_3d
- 1.280142058
- umap2_3d
- -0.937589646
- umap3_3d
- -3.263139955
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1128 | Med | Medulloblastoma | 0.913 |
| 2 | MDT-AP-0363 | Med | Medulloblastoma | 0.913 |
| 3 | MDT-AP-2869 | Med | Medulloblastoma | 0.911 |
| 4 | s0122206 | — | — | 0.910 |
| 5 | SRR10842349 | — | — | 0.909 |
| 6 | BS_TA9WP4TH | Med | Medulloblastoma | 0.908 |
| 7 | BS_G1Y281HX | Neuroblastoma | — | 0.906 |
| 8 | SRR615467 | GTEX | — | 0.906 |
| 9 | MDT-AP-1239 | Med | Medulloblastoma | 0.905 |
| 10 | MNG663 | — | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |